Whilst our primary research area has always focused on methodology and latterly the design of functional secondary structures, we are always aware that therapeutics are an important way to demonstrate the application of this chemistry. As such we have contributed to a range of disease states, ranging from cardiac targets through to anticancer and antiviral systems. Our current work in this area is focused on the application of foldamer scaffolds to disrupt protein-protein interactions in the SARS-CoV-2 virus.
1) Parijat, P.; Kondacs, L.; Alexandrovich, A.; Gautel, M.; Cobb, A. J. A.; Kampourakis, T. High Throughput Screen Identifies Small Molecule Effectors That Modulate Thin Filament Activation in Cardiac Muscle. ACS Chem. Biol. 2021, 16, 225.
2) Cobb, A. J. A.; Dell'Isola, A.; Abdulsattar, B. O.; McLachlan, M. M. W.; Neuman, B. W.; Müller, C.; Shankland, K.; Al-Mulla, H. M. N.; Binks, A. W. D.; Elvidge, W. Synthesis and antiviral activity of novel spirocyclic nucleosides.
3) Gadd, A. J.; Greco, F.; Cobb, A. J. A.; Edwards, A. D. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.
4) Dell'Isola, A.; McLachlan, M. M. W.; Neuman, B. W.; Al-Mullah, H. M. N.; Binks, A. W. D.; Elvidge, W.; Shankland, K.; Cobb, A. J. A. Synthesis and Antiviral Properties of Spirocyclic [1,2,3]‐Triazolooxazine Nucleosides.